Marvin L. White - Mar 2, 2025 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
President and CEO, Director
Signature
/s/ SoYoung Kwon, Attorney-In-Fact
Stock symbol
APVO
Transactions as of
Mar 2, 2025
Transactions value $
$0
Form type
4
Date filed
3/4/2025, 04:33 PM
Previous filing
Nov 13, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Options Exercise +8 +19.51% 49 Mar 2, 2025 Direct F1
transaction APVO Common Stock Options Exercise +6 +12.24% 55 Mar 3, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Restricted Stock Unit Options Exercise $0 -8 -50% $0.00 8 Mar 2, 2025 Common Stock 8 Direct F1, F2
transaction APVO Restricted Stock Unit Options Exercise $0 -6 -100% $0.00 0 Mar 3, 2025 Common Stock 6 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 On March 3, 2023, the reporting person was granted 38,750 (24 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024.
F3 On June 7, 2022, the reporting person was granted 28,750 (18 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023.